Algernon Pharmaceuticals Inc. CEO Christopher J. Moreau and guest Dr. David Nutt, renowned neuropsychopharmacologist and DMT consultant discuss the Company’s upcoming Phase 1 study of DMT for Stroke.
Live Interview – July 8, 2021
Recent Posts
- The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
- Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
- Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT
- SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment
- Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough
Recent Comments
No comments to show.